Sutro Biopharma Stock Forecast
NASDAQ: STROHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 15.32 0.00%
STRO analyst consensus
Consensus (14 analysts)
strong_buy
Avg. price target
$47.23+208.29%
- Strong buy 3
- Buy 10
- Hold 0
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 14 Wall Street analysts covering Sutro Biopharma (2026-10-08), 13 rate the stock a buy or strong buy, 0 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $47.23, with a high estimate of $61.00 and a low estimate of $10.00. The average target implies upside of 208.3% from the current price of $15.32.
The spread between the highest and lowest targets is 510.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for STRO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 21% |
| Buy | 10 | 71% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 1 | 7% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $10.00 | -34.73% |
| Average target | $47.23 | +208.29% |
| High target | $61.00 | +298.17% |